Publication: 27

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102
      QxMD      Google Scholar   
Citation:
Ann Oncol vol 20 (6) 1074-1079
Year:
2009
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, U10 CA032291, CA33601, CA11789, U10 CA077658, CA77406, CA47577, CA35113, CA32291, U10 CA086726, CA29165, CA41287, U10 CA035279, U10 CA045808, U10 CA045389, CA60138, CA45389, CA45808, CA35279, U10 CA114558, CA12046, U10 CA045418, CA86726, U10 CA077440, CA16450, CA77440, U10 CA041287, U10 CA035113, U10 CA047559, CA04326, CA08025, CA21060, CA47559, CA114558-02, CA47642, CA45418, CA77658, CA77298, U10 CA047642, CA31946, CA07968  
Corr. Author:
 
Authors:
           
Networks:
 
Study
CALGB-90102
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
gefitinib, chemotherapy, EGFR, transitional cell carcinoma, urothelial